U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07286266) titled 'A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)' on Dec. 12.
Brief Summary: This study specifically aims to evaluate how well GSK5733584 works in treating ovarian cancer compared to standard treatments. The study also assesses whether GSK5733584 is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Study Start Date: March 03, 2026
Study Type: INTERVENTIONAL
Condition:
Ovarian Neoplasms
Intervention:
DRUG: GSK5733584
GSK5733584 will be admin...